Introduction
============

Adrenocortical tumours (ACT) occur at all ages and have a bimodal distribution with peaks of incidence at around 5 years of age and in the 4^th^and 5^th^decades of life \[[@B1],[@B2]\]. Childhood ACTs are rare, with the annual worldwide incidence around 0.34 per million children below the age of 15 \[[@B1],[@B3]\]. In the United States, Surveillance Epidemiology and End Results (SEER) data from the National Cancer Institute show that only about 0.2% of all childhood malignancies are ACTs \[[@B4]\].

In southern Brazil (State of Paraná), the ACT incidence is 4.2 per million in the age range of 0 - 15 years \[[@B5]\] with higher prevalence in 0 - 4-year-old girls (Fig. [1](#F1){ref-type="fig"}). Over the last 40 years, more than 137 ACT patients under 19 years of age have been admitted for treatment in the Pediatric Endocrinology Unit of the Department of Pediatrics in the Clinical Hospital of the Federal University of Paraná, in Curitiba, Brazil. This hospital is a tertiary referral centre for a population of approximately 16 million people, 5 million of whom are less than 15 years of age. It should be noted that at least 5 other hospitals in our state are referral centres for childhood malignancies. In the neighbouring State of São Paulo, Marigo et al. observed that childhood ACTs accounted for 2.9% of solid tumours registered at Santa Casa de Misericordia of São Paulo over a period of 15 years, whereas in the London Hospital for Sick Children, ACTs comprised only 0.8% \[[@B6]\]. Later on, other groups in the State of São Paulo also reported a large series of ACTs in children and adolescents \[[@B7]-[@B10]\].

![**Distribution of 125 cases of childhood adrenocortical tumour by age and gender**.](1897-4287-4-2-81-1){#F1}

The population in these two Brazilian states are descendants of migrants from Portugal, Italy, Spain, Germany, Poland, Ukraine, Japan and Africa - countries where the incidence of ACTs is not increased - and a minority of the native population. The sporadic occurrence, absence of any clinical characteristics consistent with genetic disorders (i.e. Beckwith-Wiedemann and MEN1 syndromes, hemihypertrophy, congenital adrenal hyperplasia and Carney complex) or familial cancer history characteristic of Li-Fraumeni syndrome (LFS), is a common feature of the majority of Brazilian children with ACTs \[[@B5],[@B8]-[@B11]\].

Childhood ACT is often the first indicator of a familial predisposition to cancer \[[@B12]\]. Typically, germline mutations in these families were mapped to the highly conserved DNA-binding domain of the *TP53*gene (exons 5-8). However, some children who develop ACTs in the absence of familial cancer syndromes harbour germline mutations in other regions of *TP53*\[[@B13]\]. Due to ACTs having a higher incidence in our state and the absence of mutations in exons 5-9 of *TP53*, all coding regions of the gene have been examined. A germline mutation, R337H in exon 10 of *TP53*, was identified in 35 of 36 patients studied \[[@B11]\].

Because Paraná and São Paulo have extensive agricultural activities, it is tempting to speculate that environmental pollutants, such as pesticides, may pose a substantial health hazard and possibly contribute to adrenal tumorigenesis in individuals with the TP53 R337H mutations. Pesticides are widely used in Paraná without any safety guidelines. Interestingly, British investigators found an association between increased ACT incidence and pesticide use in North West England \[[@B14]\]. Supportive evidence is also forthcoming from Norway, where Kristensen et al. reported an almost 2-fold increase in the relative risk of cancer amongst 0-4-year-old children whose parents were agricultural workers \[[@B15]\].

Biological aspects of adrenocortical tumour
===========================================

Whether adrenocortical carcinomas develop from benign adenomas or are a separate disease remains to be fully determined. In our experience, all ACT cases clearly diagnosed as adenomas behaved benignly and were stage I disease (see Table [1](#T1){ref-type="table"}). Those tumours associated with virilization (VS), Cushing\'s syndrome (CS), or mixed syndrome (MS - virilization and excess of cortisol and/or mineralocorticoids) were stage II tumours. Studies on tumour clonality aimed at distinguishing carcinomas from adenomas have shown disparate results \[[@B16],[@B17]\]. At one extreme end of the spectrum, adrenocortical carcinomas are composed of a monoclonal population of cells, whereas at the other end, nodular hyperplasic adrenal tissue consists of a polyclonal cell population. In between are adenomas, where approximately half are monoclonal and half polyclonal and/or mixed \[[@B17]\]. However, in another study, almost all adenomas were monoclonal \[[@B16]\].

###### 

Staging criteria for childhood adrenocortical tumour (Sandrini et al. \[[@B5]\])

  Stage   Description
  ------- -----------------------------------------------------------------------------------------------------------------------------------------
  I       tumour totally excised; tumour vol. \<200 cm^3^, absence of metastasis, normal hormone levels after surgery
          
  II      microscopic residual tumour; tumour \>200 cm^3^, tumour spillage during surgery or persistence of abnormal hormone levels after surgery
          
  III     gross residual or inoperable tumour
          
  IV      distant metastasis

Several aspects of ACT formation are not well understood at the present time, in particular the reasons why some tumours are confined to certain dimensions and secrete exclusively one type of steroid, while others display more aggressive growth and metastasize and co-secrete various types of hormones.

In order to further understand adrenocortical tumorigenesis several mechanisms were identified from studies on rare genetic syndromes (reviewed in \[[@B18]\]), such as multiple endocrine neoplasia type 1 (*Menin gene*and locus 11q13), Carney complex (regulatory R1A subunit of protein kinase A - *PRKAR1A*gene), Beckwith-Wiedemann (IGF- II and 11p15 changes) and McCune-Albright (*GNAS1*gene) syndromes, hemihypertrophy, congenital adrenal hyperplasia (*CYP21*gene), glucocorticoid-remediable aldosteronism (hybrid gene formed by CYP11B1 and CYP11B2 genes), hereditary isolated glucocorticoid deficiency (*MC2-R*gene) and alterations of the *TP53*gene.

Further complexity of ACT tumorigenesis was highlighted in a number of recent comparative genomic hybridization (CGH) and microsatellite analysis studies aimed at detecting chromosomal alterations. These approaches identified alterations affecting various chromosomes and loci (either losses or gains of part or all of a chromosome) \[[@B17]-[@B21]\], both in adenomas and carcinomas. CGH techniques demonstrated alterations in 28% \[[@B17]\] to 61% \[[@B18]\] of adenomas. Sixty-two percent of adrenal carcinomas showed losses in several chromosomes \[[@B18],[@B20]\]. Also in carcinomas, studies using microsatellite markers revealed loss of heterozygosity (LOH)/allelic imbalance in almost all cases, at 11q13 (100%) and 2p16 (92%). Moreover, LOH at the 17p13 loci is highly specific to malignant tumours \[[@B18]\]. In 1999, our group reported a consistent gain in number of copies of chromosomal region 9q34 using CGH analysis \[[@B22]\].

More recently, gene expression profiling of ACT samples using DNA microarray technology has revealed previously unknown gene expression changes in ACTs \[[@B23]-[@B26]\]. In addition, Figueiredo et al. demonstrated the presence of high levels of DAX-1 transcripts and protein expression and amplification of SF-1 in ACTs \[[@B27]\].

However, these findings did not correlate with clinical manifestation of disease, such as tumour size, malignant or benign behaviour, sex and age.

It is known that the IGF system is important in foetal growth, and high expression of IGF-2, in concert with ACTH, occurs in human foetal adrenal development (reviewed in \[[@B28]\]). IGF-2 is also highly expressed in 85% of ACTs \[[@B29]-[@B31]\]. In addition, other components of the IGF system are defective in ACTs; for example, over-expression of IGF binding protein 2 (IGFBP2) and IGF type-1 receptor (IGF1R) proteins. IGF type-2 receptor (IGF2R) loss of function by inactivating mutations located in the DNA coding region and LOH at the IGF2R loci were reported in ACTs \[[@B32],[@B33]\]. Knowledge of normal adrenal cortex development and linkage of ACTs to other genes, such as CDKN1C \[[@B34]\], H19 \[[@B35]\], INHA \[[@B36]\], GATA-4 \[[@B37]\] and proteins such as angiopoietin, urotensin II and novH (reviewed in \[[@B28]\]), makes comprehension of the molecular events underlying adrenocortical tumorigenesis very intricate.

*TP53*mutations and tumorigenesis
=================================

Recent progress has been achieved in the understanding of adrenocortical tumorigenesis by the mapping and identification of genes associated with hereditary adrenal gland tumours (reviewed in \[[@B18],[@B38]\]). More generally, lesions either in the machinery that senses DNA damage or in the machinery that implements a response to DNA damage greatly alters the likelihood of cancer. Mutation in the tumour suppressor gene *TP53*is a key mutational event in over half of all human cancers, and mutations in *TP53*are the most frequently observed genetic change in cancer \[[@B39]\]. The high frequency with which p53 protein is functionally inactivated in human cancers indicates its pivotal role against the expansion of a population of mutated somatic cells. In many cases, *TP53*itself is mutated or deleted \[[@B40],[@B41]\].

The p53 pathway responds to stresses that can disrupt the fidelity of DNA replication and cell division. Stress signals are transmitted to p53 proteins by post-translational modification. This results in activation of p53 protein as a transcription factor that initiates a programme of cell cycle arrest, cellular senescence or apoptosis. Which of these responses prevails seems to depend on cell type, cell environment, and other factors such as oncogene expression. Evidence indicates that p53 induces growth arrest after certain types of irreversible DNA damage; although alive, such cells are genetically dead as they cannot contribute to a daughter cell population and thus constitute no further neoplastic risk \[[@B42]-[@B48]\]. The transcriptional network of p53-responsive genes produces proteins that interact with a large number of other signal transduction pathways in cells and a number of positive and negative auto-regulatory feedback loops acting upon the *TP53*response \[[@B49]\].

p53 is a 393 amino acid protein containing several functional domains: the activation domain 1 (AD1) within residues 1 to 42, the activation-domain 2 (AD2) within residues 43 to 63, the proline-rich domain (PRD) within residues 64 to 91, the sequence-specific DNA-binding-domain (DBD) within residues 100 to 300, the nuclear localization signal within residues 316 to 325, the tetramerization-domain (TD) within residues 334 to 356, and the C-terminal-basic-domain (BD) within residues 364 to 393 \[[@B39],[@B50]-[@B53]\].

*TP53*and paediatric ACT
========================

The majority of *TP53*germline mutations in cancer are localized between exons 5 and 8, the highly conserved DNA-binding-domain of the gene, although mutations located in other regions have also been described. Highly penetrant *TP53*germline mutations are identified in over 77% of families with Li-Fraumeni syndrome (LFS), an autosomal dominant inherited cancer syndrome characterized by the occurrence of a variety of cancers diagnosed at young ages \[[@B54]-[@B58]\]. In patients with LFS, ACT accounts for 3% of all tumours occurring at any age and for 10% of childhood ACTs \[[@B13]\]. Thus, *TP53*mutations appear to increase ACTs predisposition in children. In North America and Europe, 50-80% of children with apparently sporadic ACTs carried *TP53*germline mutations \[[@B13],[@B59]\].

Functional analysis of the *TP53*germline mutation described in patients from Paraná showed that in contrast to *TP53*R248W, the *TP53*R337H mutant and wild type *TP53*were able to suppress colony growth of SaOs-2 cells lacking endogenous p53. In addition, in human H1299 lung carcinoma cells, which also lack endogenous p53, ectopically expressed *TP53*R337H mutant was competent to induce apoptosis. Taken together these data indicate that the R337H mutant retains p53 activity at physiological conditions \[[@B11]\].

*TP53*mutation and paediatric ACT in southern Brazil
====================================================

*TP53*R337H is present in 97% of all cases of children with ACT treated in the State of Paraná \[[@B11]\]. The same mutation was reported occurring at a prevalence of 75 and 77.7% by two independent groups of investigators in the neighbouring State of São Paulo \[[@B8],[@B9]\]. The mutation was also identified in 5 of 37 and in 1 of 5 adult patients studied by the latter groups, respectively. Interestingly, adult patients who tested positive for the mutation were all young (age range 19 to 36 years).

Chompret et al. reported the same germline mutation in a 4-yr-old girl with sporadic ACT \[[@B60]\]. Varley et al. analysed a panel of 14 cases of sporadic childhood ACTs \[[@B13]\]. *TP53*germline mutations were identified in over 80% and in one case the *TP53*R337H mutation was present in a tumour, with the complete loss of the wild type allele; however, they were unable to determine whether this mutation was inherited or acquired.

Recently, DiGiammarino et al. were able to expose subtle defects of the mutant protein while studying its behaviour, *in vitro*, under variations in pH and temperature \[[@B61]\]. From their study, it was shown that tetramer formation of the R337H p53 mutant becomes significantly less stable as pH increases toward the physiological range between 7 and 8. A substantial fraction of mutant p53 R337H variants remain unfolded at pH 8 and at 37°C (\>70% unfolded), whereas wildtype p53 is fully folded under the same conditions \[[@B61]\]. Previous to this study, Davison et al. using circular dichroism spectroscopy were also able to show the effects of temperature on the stability of the p53 mutant protein in families with LFS and Li-Fraumeni like syndrome with *TP53*L344P and *TP53*R337C mutations, respectively, located in the tetradimerization zone of *TP53*\[[@B62]\]. The cause of the *TP53*R337H mutation is presently unknown. The demonstration of different markers surrounding and within the mutated *TP53*gene in various unrelated subjects strongly indicates that it is derived from diverse ancestors \[[@B11]\]. In contrast, Pinto et al. studied 22 patients (16 children and 6 adults) from the State of São Paulo and concluded that the *TP53*R337H germline mutation arose from a single common ancestor \[[@B63]\].

Several lines of evidence show that the *TP53*R337H mutation is strongly related to ACT in children in southern Brazil: a) the families do not have a common ancestry; b) *TP53*R337H is not a common polymorphism among southern Brazilians; c) the loss of heterozygosity with retention of the mutant allele in the tumour cells, and d) the mutant p53 protein is highly expressed in the ACTs \[[@B11],[@B64]\].

Over 927 individuals were tested for the *TP53*R337H mutation, 232 from the non-carrier and 695 (including 40 probands) from the carrier parental line. In the carrier parental line, the mutation tested positive in 240 individuals (34.5%) and in none of the non-carrier parental line \[[@B65]\]. In this group, fifty percent of the parents and grandparents evaluated carried the *TP53*R337H mutation. Thus, there is no evidence of *de novo*mutation. All probands carried the mutation in the heterozygous state in the series of cases from Paraná. In the State of São Paulo, Latronico et al. described one patient who was homozygous for the mutation and whose parents both carried the mutation in a heterozygous state \[[@B8]\].

The estimated penetrance of ACT among carriers of the *TP53*R337H mutation is 9.9% (95% CI, 8.7-11.1%) and it is greater in the 8 kindreds with multiple cases of ACT (12.5%; 95% CI, 10.2-14.6%) than in kindreds with a single case (8.5%; 95% CI, 7.3-9.7%) \[[@B65]\]. Varley et al. had already described *TP53*mutations in 14 cases of childhood ACT with equally low cancer penetrance \[[@B13]\].

Although the penetrance of this mutation is low, close monitoring of children at risk of ACT is advisable in order to detect the presence of tumour as early as possible, thereby improving outcome. Relevant in this regard are the data of Pereira et al., where 65 children (siblings and first-degree relatives), 0.25 to 14.6 years of age and all carriers of the *TP53*R337H mutation, have been followed for three consecutive years, on a clinical, laboratory and imaging basis. There is currently no evidence of ACT developing in these children. The aim of the study is to follow these individuals for as long as possible, in order to acquire more data to better define the penetrance of this mutation \[[@B66]\].

Clinical features
=================

We have conducted a comprehensive review of 125 patients from 137 who attended our service between 1966 and December 2005.

Ninety patients were girls (72%); median age of the entire group was 3.2 years, two thirds being aged 0-4 years (5 patients presented with an ACT at birth, Fig. [1](#F1){ref-type="fig"}). The ratio of girls to boys was 2.6:1 for this group and 3.5:1 in patients below 4 years. The mean time interval between the appearance of the first clinical signs and the diagnosis of disease was 11 months. None of the patients had conspicuous African, Brazilian, or Japanese ancestry.

Virilization alone was present in 51.2% of patients; virilization associated with Cushing\'s syndrome (CS) occurred in 42.4% of patients. One patient exhibited pure CS while another displayed isolated hypertension. Endocrine silent tumours comprised 4.8% of all patients. Percentages of occurrence of the main clinical signs (precocious puberty, clitoris or penis hypertrophy, coarse voice, hypertension, facial hyperaemia, weight gain, hirsutism, accelerated growth velocity, etc.) do not differ much from those in a group of 58 children studied by Sandrini et al. in 1997 \[[@B5]\].

Hypertension in the course of ACTs deserves special attention, especially in those patients with mixed syndromes (virilization and excess of cortisol and/or mineralocorticoids). Not infrequently it is severe enough to cause hypertensive encephalopathy with seizures. Aggressive therapy with ECA inhibitors and furosemide is routine in our service. After complete tumour removal hypertension does not abate rapidly; indeed, in some cases it persists for two to four weeks. The frequency of palpable abdominal mass is less than that reported in 1997, possibly due to increasing awareness, by paediatricians, of the possibility of adrenal tumour in young children with precocious puberty. Curiously, purple striae occurred in only 2 patients, although hypercortisolism was present in almost half of all patients. Vena cava invasion, extending to the right atrium, is usually associated with large and long-standing tumours; it is rarely present in the course of small tumours. Both glands were equally affected and concomitantly bilateral ACT has never been recorded. However, a 3.5-yr-old-girl who had a small tumour completely removed from the left adrenal presented with a tumour in the right gland 12 years later, with pulmonary metastasis and vena cava and right atrium invasion.

Diagnosis
=========

At present, our routine hormonal profile for patients suspected of having ACT includes measurements of serum (8am, 11pm) cortisol, testosterone, DHEA-S, androstenedione, 17-hydroxyprogesterone, aldosterone, and PRA.

Several different imaging techniques have been used to confirm the presence of tumour, for staging the disease and to help plan the surgical approach. Magnetic resonance (MR), computerized tomography (CT) and ultrasound (US) are used to confirm the presence of the tumour, to visualize invasion of close structures (liver, pancreas, kidney and diaphragm), metastasis and venous invasion. However, it should be stressed that depending on the equipment used, very small tumours may be missed when investigated by US alone. All newly diagnosed patients are scanned with CT to assess the level of metastasis, if any, in the lung and liver, as these are the most common sites of spread. Calcifications are frequent and can present either as small focal inclusions or extensive linear and amorphous deposits. Whole body fluoro-deoxyglucose positron-emission tomographic imaging (PET-SCAN) has been incorporated into the diagnostic procedures of ACT \[[@B67],[@B68]\].

Treatment
=========

Surgery
-------

Complete resection of tumour and local lymph nodes is the single most important procedure in successful treatment of ACT. *En bloc*resection, which may include the adjacent structures invaded by the tumour, is required in cases of large and invasive tumours. Due to the friability of the tumour, rupture of the capsule and tumour spillage can occur.

A hundred and twenty-three out of 125 patients have been operated on. In 86.2% of the cases the tumour was completely excised; in 10.6% the tumour was inoperable and in 3.2% only partial resection was performed.

Venous tumour invasion, especially of the vena cava, occurred in 19.6% of 92 patients in which it was carefully searched for. US, MR and cavography have been used to look for the presence of venous invasion. In cases where the tumour invades the right atrium the concurrence of a cardiovascular surgeon is mandatory. In such cases, extracorporeal circulation is recommended.

Surgical resection is also indicated for recurrent local disease or metastases. Multiple surgical interventions may be needed for recurrence, providing prolonged survival or even cure. One patient is free of disease 20 yrs after being operated on twice for tumour bed recurrence and once for hepatic metastases.

Chemotherapy
------------

Chemotherapy has been used to treat metastatic ACT and for those cases of large inoperable or partially excised tumour and for recurrences. Despite the use of different protocols of chemotherapeutic agents, none has emerged that has been shown to be sufficiently effective to be widely adopted. Mitotane has been used since the 1960s, initially for adult patients \[[@B69]\]. It inhibits adrenocortical hormone biosynthesis and causes destruction of adrenal cells \[[@B70]\]. While low doses (\<3 g/day) suppress steroid synthesis and regression of clinical signs, with higher doses (\>3 g/day) an adrenolytic effect is observed. It should be stressed that no correlation exists between suppressed steroid synthesis and tumour regression \[[@B71]\]. After years of enthusiasm for mitotane that peaked during the mid-1980s, subsequent large trials showed transient partial responses and no complete responses \[[@B70]\]. Despite objective response to mitotane observed in some patients, the survival rate was not significantly increased \[[@B72]\]. A clinical trial with mitotane conducted in our service included 10 consecutive children with stages II and III disease. Only a single patient with an inoperable tumour had a partial response, which permitted curative surgery; the patient has been disease-free for the last 16 yrs (unpublished data). Based on the experience of Berruti et al., who showed favourable results with a combination of mitotane with cisplatin, etoposide, and doxorubicin, we have adopted this scheme with a lower dose of mitotane \[[@B66],[@B73]\]. Notwithstanding, low doses of mitotane produced side effects in a sizable proportion of patients, which included mainly nausea, vomiting, anorexia and mood changes. Despite the observation of complete remission of metastasis, the time of observation and the limited number of patients so far treated do not permit us to draw any firm conclusions \[[@B66]\]. Paediatric endocrinologists must have in mind the drawbacks derived from mitotane use and therefore patients should be followed closely. For instance, in order to avoid adrenal insufficiency double to triple doses of glucocorticoids and mineralocorticoids are needed.

Prognosis
---------

Because of the heterogeneity and rarity of ACTs, prognostic factors have been difficult to establish. The diagnosis of ACT is made on the basis of gross and histological appearance of tissue obtained at surgery. Classification of ACT as having a malignant or benign potential based only on histopathology is difficult \[[@B5]\]. However, all 20 patients from our personal experience who have received the diagnosis of adenoma are still alive.

Due to difficulties in correlating the histopathological findings to ACT prognosis, clinical characteristics, laboratory profile, therapeutic approach and presence or absence of metastasis were evaluated in relation to outcome. A multivariate analysis showed that only tumour size was significantly associated with survival \[[@B5]\]. Subsequently, data of the International Pediatric Adrenocortical Tumor Registry (IPACTR), based on the evaluation of 254 patients, 43.4% of whom were from our service and 36.0% from other Brazilian centres, showed that tumour stage I (Table [1](#T1){ref-type="table"}), virilization alone and age 0 - \<4 years, were significantly related to greater probability of event-free survival \[[@B5],[@B74]\]. On the other hand, incomplete tumour excision, capsule rupture during surgery and presence of intravenous thrombi were linked to a bad prognosis.

Concluding remarks
==================

Several characterized TP53 polymorphisms showed altered regulation of p53 protein post-translational modifications, protein stability, nuclear localization and downstream signalling. Restoration of TP53 functions, in particular TP53-dependent apoptosis, is an attractive cancer therapeutic strategy. To exploit TP53-dependent apoptosis for the destruction of cancer cells, many studies have focused on strategies that preferentially activate TP53 to induce proapoptotic target genes. It is already known that there is great heterogeneity of p53 responsiveness among different tissues and during different stages of development. Thus, it appears that the regulation of p53 responsiveness plays an important role not only in cancer but also during embryogenesis and in normal tissue physiology. Therefore any individual who has poor p53 responsiveness to DNA damaging agents in internal tissues may be at a higher risk of developing cancer in these tissues. Two distinct prognostic groups of patients with ACT can be recognized: one with very poor prognosis (patients with metastatic disease or gross residual tumour) and one with a very good prognosis (patients with completely excised tumour of small size or adenoma histology). It would be of great interest to identify additional prognostic molecular markers within poor p53 responders more susceptible to ACT and possibly combine cancer-preventive therapies aimed at modulating TP53 activity to induce apoptosis in tumour cells. More importantly, future studies should delineate more complex genotypes associated with p53 mutations, novel elements in p53 cellular response and deregulated cellular processes in ACT. Indeed, recent molecular biology techniques and genomic approaches have identified key cellular processes fundamental for tumour development and progression.

Many questions remain unexplained in childhood ACTs: a) Why is only one adrenal gland affected? b) Could the hormonal milieu (oestriol during foetal growth and oestradiol in the first two years of life) underlie sex differences observed in ACT occurrence? c) Do cells from the adrenal cortex foetal zone escape apoptosis by the concerted action of several genes and gene products, making them susceptible to tumorigenesis? d) What endogenous and environmental factors determine tumour behaviour? e) Will prospective studies of patients and relatives with TP53 R337H mutation show whether, in the longer term, ACT can appear in the contra-lateral gland or play a role in other types of tumour?
